{"title":"Advances in the relationship between AP-1 and tumorigenesis, development and therapy resistance.","authors":"Xinni Xue, Zhiwei Li, Jiahui Zhao, Ziyi Zhao, Zhihang Li, Yong Li, Yawen Liu, Huan He","doi":"10.1007/s12672-025-01783-1","DOIUrl":null,"url":null,"abstract":"<p><p>Activating protein 1 (AP-1) is a transcription factor composed of several protein families, Jun proteins and Fos proteins are the components of AP-1. AP-1 is involved in various cellular processes, such as proliferation, differentiation, apoptosis and inflammation. For tumor cells, AP-1 is considered to be a driver whose activity is associated with dysfunction and the onset, development, invasion, and migration of cancer. In addition, AP-1 has been reported to be involved in the drug resistance and radiation resistance of tumor cells during the treatment process. Therefore, AP-1 is a potential target for cancer therapy. At present, a number of inhibitors targeting AP-1 have been developed and have shown certain anti-cancer effects. However, due to the complex structure and function of AP-1, different structures of AP-1 show different effects in different tumor cells, and more studies are needed to reveal its mechanism of action. This article introduces the relationship between AP-1 and tumor development, summarize the current studies and developments of AP-1 related drugs, and provide the future development values of AP-1.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"61"},"PeriodicalIF":2.8000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11747019/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discover. Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-025-01783-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Activating protein 1 (AP-1) is a transcription factor composed of several protein families, Jun proteins and Fos proteins are the components of AP-1. AP-1 is involved in various cellular processes, such as proliferation, differentiation, apoptosis and inflammation. For tumor cells, AP-1 is considered to be a driver whose activity is associated with dysfunction and the onset, development, invasion, and migration of cancer. In addition, AP-1 has been reported to be involved in the drug resistance and radiation resistance of tumor cells during the treatment process. Therefore, AP-1 is a potential target for cancer therapy. At present, a number of inhibitors targeting AP-1 have been developed and have shown certain anti-cancer effects. However, due to the complex structure and function of AP-1, different structures of AP-1 show different effects in different tumor cells, and more studies are needed to reveal its mechanism of action. This article introduces the relationship between AP-1 and tumor development, summarize the current studies and developments of AP-1 related drugs, and provide the future development values of AP-1.
激活蛋白1 (activated protein 1, AP-1)是由多个蛋白家族组成的转录因子,Jun蛋白和Fos蛋白是AP-1的组分。AP-1参与多种细胞过程,如增殖、分化、凋亡和炎症。对于肿瘤细胞,AP-1被认为是一种驱动因子,其活性与功能障碍以及癌症的发生、发展、侵袭和迁移有关。此外,有报道称AP-1在治疗过程中参与了肿瘤细胞的耐药和耐辐射。因此,AP-1是癌症治疗的潜在靶点。目前已开发出许多靶向AP-1的抑制剂,并显示出一定的抗癌作用。但由于AP-1结构和功能复杂,不同结构的AP-1在不同肿瘤细胞中的作用也不同,其作用机制有待进一步研究。本文介绍了AP-1与肿瘤发展的关系,综述了AP-1相关药物的研究进展,并提出了AP-1未来的开发价值。